Revlimid (Lenalidomide) Now FDA Approved as First-Line ...
Multiple myeloma, a cancer affecting plasma cells, leads to bone destruction and marrow failure. Incidence is higher in men and those over 65. Advances in therapy, including immune modulators and proteasome inhibitors, have improved survival rates. Lenalidomide, approved for first-line treatment, shows significant efficacy but comes with risks like embryofetal toxicity and hematologic issues.
Reference News
Multiple myeloma, a cancer affecting plasma cells, leads to bone destruction and marrow failure. Incidence is higher in men and those over 65. Advances in therapy, including immune modulators and proteasome inhibitors, have improved survival rates. Lenalidomide, approved for first-line treatment, shows significant efficacy but comes with risks like embryofetal toxicity and hematologic issues.